Identification of BRCA1-Associated RING Domain 1 Mutation as a Novel Indicator for Constructing a Prognostic Nomogram in Multiple Myeloma: A Retrospective Single-Center Study.

This study aims to investigate the prognostic value of BARD1 (BRCA1-associated RING domain 1) in newly diagnosed multiple myeloma (NDMM), which has not been well defined previously. This is a retrospective analysis containing 74 NDMM patients. Clinical data, including R2-ISS and BARD1 gene mutation status, were employed to construct a nomogram using Cox's proportional hazards model. Univariate analysis revealed a significant correlation between R2-ISS, BARD1 gene mutations and both Overall Survival (OS) and Progression-Free Survival (PFS) (P < 0.01). Notably, the constructed nomogram models, comprising R2-ISS and BARD1 gene mutations, exhibited excellent predictive performance for PFS and OS in both training and validation sets. The nomogram, innovatively combining the BARD1 gene with R2-ISS staging, effectively predicts the prognosis of NDMM. Although this study is limited by the relatively small number of patients with BARD1 mutations, the outcome may aid us in comprehending the role of genetic mutations in NDMM and further in the investigation of drugs targeting this gene.